Abstract
Gold nanoparticles stabilized with polyethylene glycol were used to study their cytotoxicity and antiviral activity against HIV-1 in the laboratory. The HeLa-CD4-LTR-B-gal cell line was used with gold nanoparticles to determine the cell viability using luminescent assay. The 50% cytotoxicity concentration, IC50 of gold nanoparticles was found to be 1.12 ± 0.05 mg/ml. M-tropic, T-tropic, dual tropic and resistant isolates were inhibited by gold nanoparticles and their inhibition concentration ranged from 0.05 to 0.12 mg/ml. The mechanism of gold nanoparticles against HIV-1 is not clear but it inhibits the HIV-1 fusion. In this study, the gold nanoparticles were used to analyze their mode of antiviral activity and the experimental results showed that they inhibit the viral entry by binding with gp120 and prevent CD4 attachment. These properties of gold nanoparticles make them as an effective antiviral inhibitor.
Keywords: Gold nanoparticle, cytotoxic, broad - spectrum, immune system, viral inhibition, HIV-1, AIDS, antiviral, inhibitor, concentration
Current HIV Research
Title:Gold Nanoparticles as an HIV Entry Inhibitor
Volume: 10 Issue: 8
Author(s): S. Vijayakumar and S. Ganesan
Affiliation:
Keywords: Gold nanoparticle, cytotoxic, broad - spectrum, immune system, viral inhibition, HIV-1, AIDS, antiviral, inhibitor, concentration
Abstract: Gold nanoparticles stabilized with polyethylene glycol were used to study their cytotoxicity and antiviral activity against HIV-1 in the laboratory. The HeLa-CD4-LTR-B-gal cell line was used with gold nanoparticles to determine the cell viability using luminescent assay. The 50% cytotoxicity concentration, IC50 of gold nanoparticles was found to be 1.12 ± 0.05 mg/ml. M-tropic, T-tropic, dual tropic and resistant isolates were inhibited by gold nanoparticles and their inhibition concentration ranged from 0.05 to 0.12 mg/ml. The mechanism of gold nanoparticles against HIV-1 is not clear but it inhibits the HIV-1 fusion. In this study, the gold nanoparticles were used to analyze their mode of antiviral activity and the experimental results showed that they inhibit the viral entry by binding with gp120 and prevent CD4 attachment. These properties of gold nanoparticles make them as an effective antiviral inhibitor.
Export Options
About this article
Cite this article as:
Vijayakumar S. and Ganesan S., Gold Nanoparticles as an HIV Entry Inhibitor, Current HIV Research 2012; 10 (8) . https://dx.doi.org/10.2174/157016212803901383
DOI https://dx.doi.org/10.2174/157016212803901383 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Prospective Clinical Applications of CRF Peptide Antagonists
Current Molecular Pharmacology FGF10 and FGF21 as Regulators in Adipocyte Development and Metabolism
Endocrine, Metabolic & Immune Disorders - Drug Targets Investigation of <i>ACE rs4646994, MTHFR rs1801133</i> and <i>VDR rs2228570</i> Genotypes in Jordanian Patients with Fibromyalgia Syndrome
Endocrine, Metabolic & Immune Disorders - Drug Targets Good, Bad, Mobile Elements: Genome’s Most Successful “Parasites” as Emerging Players in Cell and Organismal Aging
Current Pharmaceutical Design Critical Illness in Obstetric Patients: Venous Thromboembolism in Pregnancy
Current Women`s Health Reviews Brutons Tyrosine Kinase as a New Therapeutic Target
Anti-Cancer Agents in Medicinal Chemistry Juvenile Systemic Lupus Erythematosus
Current Pediatric Reviews LPS-induced Murine Neuroinflammation Model: Main Features and Suitability for Pre-clinical Assessment of Nutraceuticals
Current Neuropharmacology Nutraceuticals as Lipid-Lowering Treatment in Pregnancy and Their Effects on the Metabolic Syndrome
Current Pharmaceutical Biotechnology Haptoglobin Phenotype May Alter Endothelial Progenitor Cell Cluster Formation in Cerebral Small Vessel Disease
Current Neurovascular Research Bone and the Kidney: A Systems Biology Approach to the Molecular Mechanisms of Renal Osteodystrophy
Current Molecular Medicine Episensitization: Therapeutic Tumor Resensitization by Epigenetic Agents: A Review and Reassessment
Anti-Cancer Agents in Medicinal Chemistry Phosphoinositide-3-kinases as the Novel Therapeutic Targets for the Inflammatory Diseases: Current and Future Perspectives
Current Drug Targets Fertility Preservation in Women After the Cancer
Current Pharmaceutical Design The Role of Epigenetics in the Progression of Non-Alcoholic Fatty Liver Disease
Mini-Reviews in Medicinal Chemistry Legumes: A Healthy and Ecological Source of Flavonoids
Current Nutrition & Food Science Current Treatments of Primary Sclerosing Cholangitis
Current Medicinal Chemistry New Approaches for Antithrombotic Antiplatelet Therapies
Current Medicinal Chemistry Electronic Recording of Growth Hormone Dosing History: The Easypod™ Auto-Injector
Current Drug Therapy Glioma Therapy: A Novel Insight in the Immunotherapeutic Regime with T11TS/SLFA-3
Central Nervous System Agents in Medicinal Chemistry